Drug Profile
Adjuvanted Hepatitis B vaccine (Recombinant) - Dynavax Technologies
Alternative Names: HBsAg-1018; HBV vaccine preventative - Dynavax; HBV-ISS preventative vaccine; Hepatitis B Vaccine (Recombinant) Adjuvanted; Hepatitis B vaccine 1018-ISS conjugate - Dynavax; Hepatitis B vaccine preventative - Dynavax; HEPLISAV; HEPLISAV-B; V270Latest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Hepatitis B vaccines; Oligonucleotides; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 03 Aug 2023 FDA assigns PDUFA action date of 13/05/2024 for Adjuvanted Hepatitis B vaccine (Recombinant) for Hepatitis B
- 03 Aug 2023 US FDA accepts sBLA for Adjuvanted Hepatitis B vaccine (Recombinant) for Hepatitis B for review
- 28 Feb 2023 Registered for Hepatitis B (In adults, In the elderly, Prevention) in United Kingdom (IM)